(Q38570731)

4 September 2017

Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers (English)

1 reference

4 September 2017

0 references

1 reference

1 reference

H Okada

1

1 reference

4 September 2017

Y Doken

series ordinal

2

1 reference

4 September 2017

Y Ogawa

series ordinal

3

1 reference

4 September 2017

H Toguchi

series ordinal

4

1 reference

4 September 2017

1 August 1994

1 reference

4 September 2017

Pharmaceutical Research

1 reference

4 September 2017

11

1 reference

4 September 2017

8

1 reference

4 September 2017

1143-1147

1 reference

Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals

4 September 2017

1 reference

12 December 2020

One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats

1 reference

12 December 2020

Preparation and in vitro degradation properties of polylactide microcapsules.

1 reference

12 December 2020

In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers

1 reference

12 December 2020

Long-acting delivery systems for narcotic antagonists. 1

1 reference

12 December 2020

A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata

1 reference

12 December 2020

Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate

1 reference

12 December 2020

Tissue response to biodegradable injectable microcapsules

1 reference

12 December 2020

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

12 December 2020

Tissue response to bioerodible, subcutaneous drug implants: a possible determinant of drug absorption kinetics

1 reference

12 December 2020

Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate

1 reference

12 December 2020

Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1018936815654

1 reference

4 September 2017

1 reference